Virgin Trains may be speeding into Texas. Photo courtesy of Virgin Trains

Transportation company steers talk of high-speed trains between Houston, Austin, and San Antonio

ALL ABOARD?

You've likely heard of the proposed high-speed "bullet" train that would connect Houston and Dallas, as well as the proposed transportation-in-a-tube concept that would link Houston, Austin, Dallas, San Antonio, and Laredo.

Now, another possible alternative to planes, Amtrak trains, and automobiles has chugged into the picture.

Virgin Trains USA, a transportation startup that plans to trade its shares on the Nasdaq stock exchange, is exploring two high-speed routes in Texas — one tying together Houston, Austin, and San Antonio, and the other between Houston and Dallas. All four of those cities are plagued by ever-increasing traffic tie-ups.

There's no word yet on when these routes might take shape. At this point, they're merely ideas, and ahead of the company going public, officials at Virgin Trains are staying mum.

In all, Virgin Trains has outlined seven potential routes in the U.S. beyond what it already has on the drawing board.

"Our goal is to build railroad systems in North America that connect major metropolitan areas with significant traffic and congestion," the company says in a filing with the U.S. Securities and Exchange Commission.

Virgin Trains aims to tie together heavily populated cities separated by 200- to 300-mile distances that are "too long to drive, too short to fly." It wants to run the trains along existing transportation corridors — rail, highway or a combination of the two — "to cost-effectively build our systems, as opposed to developing entirely new corridors at potentially significantly higher costs."

If the Virgin name sounds familiar, it should. British billionaire Sir Richard Branson's Virgin Group is a minority investor in Virgin Trains, which already operates a South Florida route between Miami and West Palm Beach. West Palm Beach-to-Orlando and Orlando-to-Tampa routes also are in the works in Florida, in addition to a Los Angeles-to-Las Vegas route. Virgin's other transportation investments include airlines and space travel.

Jim Mathews, president and CEO of the Rail Passengers Association, says he's on board with the Branson-backed Virgin Trains venture — not as an "anti-Amtrak" move but as an advancement in U.S. passenger rail travel.

"Speaking from the experience of someone who spent almost his entire career watching Sir Richard innovate, invest, and take risks, I firmly believe this could be a real shot in the arm for passenger rail in the United States," Mathews writes on the association's website. "Like all entrepreneurs, Sir Richard isn't afraid to fail, and he has made a few bad bets in the past. But he's also made some very good ones, and has transformed not just travel but philosophies wherever he has gone."

------

This story originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.

Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”